DTx East 2020
3rd Annual

DTx East 2020

September 16 - 18, 2020 | EDT Timezone

Accelerating Digital Therapeutics into the Hands of Patients

 

Re-engineered for Online

 

Find Out More Agenda

Partners

Knowledge Partners
Knowledge Partner

Biorasi is a catalyst for growth, innovation and evolution in the field of clinical research. We move the industry forward, improving results for our partners, and outcomes for their patients.

Learn More

Knowledge Partner

We set our sight on a simple, but powerful vision to advance life science services toward a healthier world.

The journey began when Water Street Healthcare Partners and JLL Partners joined forces to acquire and combine the most comprehensive platform of life sciences services in the industry. Together, we are EVERSANA.

We offer more than 500 clients – from start-ups to established global pharmaceutical leaders – the services they need to bring critical therapies to market while improving the lives of patients around the world.

Learn More

Knowledge Partner

Ieso Digital Health is a biotechnology company whose mission it is to harness advanced technology and clinical science to deepen the understanding of the causes, symptoms and treatments of mental health problems.

By delivering psychological care to patients using the Ieso online therapy platform, a combination of data science, and advanced analytics can be used to develop digital therapeutics, education and training, and AI tools, to change the way mental healthcare is delivered across the world.

Ieso’s employees are dedicated to building a new paradigm in mental health science; building a complete understanding of the root causes of mental health conditions and developing interventions that will address the personal, societal and economic impacts of mental illness, paving the way for a world where everyone has access to the help they need, when they need it.

Learn More

Knowledge Partner

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry dedicated to delivering unique and actionable insights. Formed through the merger of IMS Health and Quintiles, IQVIA has approximately 67,000 employees worldwide.

Learn more at www.iqvia.com

 

Knowledge Partner

Noom is the world’s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their habits for the long-term. More than 50 million people have benefited from Noom’s behavior change courses.

The company is headquartered in New York City with offices in Seoul and Tokyo.

Learn More

Knowledge Partner

TopLine Power® is what Simon-Kucher is all about. We help clients grow revenue through optimization of strategy, pricing, marketing, and sales across industries.

We are a thought leader in these topics at the intersection of digitalization and life sciences, positioning our clients thrive in the healthcare industry of the future.

Learn More

Supporters
Digital Therapeutics Commercialization Consultants

DTxCC: a boutique consultancy focused solely on Digital Therapeutics and Digital Health commercialization

We specialize in go-to-market strategy development:

– Market Access and  Reimbursement
– Business models development
– Data monetization

Our Payer Advisory Council provides actionable insight

Custom qualitative research
– One-one-one interviews

Advisory board meetings
– Virtual
Live face-to-face meetings

Learn More

Supporter

JAZZ Venture Partners invests in companies that extend the boundaries of human performance — improving how we live, learn, work, play, and experience the world.

We seek breakthroughs at the intersection of digital technology and neuroscience that are influencing the human experience, such as augmented reality, artificial intelligence, immersive gaming, and closed-loop human-computer systems.

Our portfolio companies are unlocking human potential in health, mind-body wellness, accelerated learning and training, sports, entertainment, and the enterprise.

Learn More

DTx East goes online for 2020

With Digital Therapeutics hotter than they’ve ever been, the need to meet and learn together is greater than ever before. As an industry, we cannot afford to put things on hold.

DTx East 2020 has been completely re-engineered to deliver the best networking experience together with exciting new learning opportunities.

DTx East goes online for 2020
Key Features
Dynamic Networking

Replicate those all-important ‘water cooler’ moments through randomly assigned networking or join topic-associated discussions to find those with similar interests to you. Scroll through the entire attendee list to message your fellow attendees, schedule 1-2-1 video calls, or create your own private session rooms for group discussions. DTx East will enable you to meet more leaders from across the industry than ever before!

Interactive Learning

The agenda is purposely built to provide an engaging and interactive learning experience. Integrated polls, topic-focused roundtables, Q&A with speakers, “Open-Mic” discussions, and more, you will be able to accelerate your knowledge of Digital Therapeutics as they continue their meteoric rise. The ability to actively or passively be involved in these learning opportunities is yours!

Meeting Point DTx East
Personalized Participation

The Digital Platform lets you create your own personal agenda. You can attend live sessions, watch on-demand content, take part in open networking sessions, or take a break whenever suits you. Seamlessly hop between learning and networking at any time. Look through the program and slot sessions directly into your calendar, to help fit the conference around the day job. All of this from the comfort of your own home.

The DTx Series helped shape the conversations in this new digital health category from the beginning. All the key players show up to continue the conversation and I am looking forward to the virtual experience this year. I wouldn’t miss it for the world.

Mette Dyhrberg, CEO, Mymee, Inc.

I am excited to be part of DTx East this year, being able to virtually connect with peers is crucial for the industry. I am interested in learning more from other leaders how they plan to adapt to the new reality we are living in and the impact COVID-19 will have on the future of medicine in the US.

Joe Perekupka, CCO, Palo Alto Health Sciences

DTx conferences are excellent places to collaborate with top leaders and stay current on the often complex and evolving trends shaping our investments – all while being part of a passionate, growing community of entrepreneurs.

Elan Tye, Principal, JAZZ Venture Partners

The DTx series is more than a conference – it’s become a community with mutual interest in advancing digital therapeutics.

David Stevenson, Managing Director, Merck Global Health Innovation Fund

Speaker Faculty

David Klein
David Klein
Chief Executive Officer
Click Therapeutics
David Klein
Chief Executive Officer
Click Therapeutics

Former Managing Director at Opus Point Partners which created, financed, & operated 10+ science companies including Cougar Biotechnology (CGRB), Chelsea Therapeutics (CHTP), TG Therapeutics (TGTX), Assembly Biosciences (ASMB), Tracon Pharmaceuticals (TCON), Fortress Biotech (FBIO), and Ziopharm Oncology (ZIOP)
Co-Founder & Owner at Klein Sun Gallery, America’s leading Chinese contemporary art gallery
Guest Lecturer, Biotechnology Program at Columbia University & 17+ years life science industry experience
Former Senior Consultant at Pfizer & Strategic Advisor at publicly traded & privately held life science companies
B.A., Brandeis University

Liz Kwo
Liz Kwo
Medical Director, Digital Health
Anthem
Liz Kwo
Medical Director, Digital Health
Anthem

Dr. Liz Kwo is an experienced healthcare executive with 15+ years specialized in building and scaling digital healthcare products to provide high quality care, leveraging predictive and prescriptive analytics to improve outcomes. Her current role at Anthem is to create digitized, automated, and continuously improved frictionless patient and provider experience that drives down cost of care. She has worked in remote patient monitoring for Medtronic, American Well as the VP of Provider Networks for telehealth, and is an active angel investor in the healthcare community, with a specific interest in technology-enabled healthcare delivery such as RubiconMD. She founded multiple venture-backed companies in educational technology (sold to CVC private equity firm in 2014), digital healthcare, and healthcare supplies and is passionate about creating seamless tailored experiences for enrolling patients and building on-demand data driven insights to support national employer clients.

Dr. Kwo has extensive experience in healthcare technology product development and commercialization, P&L, B2B/B2C marketing & sales, strategic partnerships, & post-merger integration. A practicing physician in urgent and preventive care, Dr. Kwo’s clinical expertise allows her to translate ideas from bench to bedside. She is also a lecturer in the Harvard-MIT HST Program and an Instructor of Medicine at Harvard Medical School.

Dr. Kwo has an MD from Harvard Medical School, MBA from Harvard Business School, MPH from Harvard TH Chan School of Public Health, and a BA from Stanford University. She completed her residency at Harvard Preventive Care and is Board Certified in Preventive Care and Occupational Medicine.

Konstantin Mehl
Konstantin Mehl
Founder & President
Kaia Health
Konstantin Mehl
Founder & President
Kaia Health

Kaia Health Inc. was founded with the aim to create evidence-based applications for self-management of chronic diseases to reflect the growing evidence of patient empowerment with effective therapies. Treatments which place patients in the driver’s seat of disease management and offer non-pharmacological alternatives are rapidly gaining importance in almost any chronic illness- from pain conditions to neurodegenerative diseases.

Kaia aims to create interdisciplinary digital approaches that empower patients to take control of the management of their diseases at low costs and to democratize access to required lifestyle changes following onset of a chronic disease. To achieve this, Kaia brings together experts in each of the medical fields in the creation of content and applications. This approach is paired with technological innovations to increase patient motivation, ensure correct exercise execution and monitor disease activity. Kaia’s first app democratizes the access to the multimodal back pain therapy. Pilot studies have consistently shown enduring pain reduction in users. This effect is currently being reproduced in RCTs. Kaia’s late stage pipeline ranges from COPD to osteoarthritis and Parkinson’s.

Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015. He now builds a digital therapeutics company called Kaia Health. He holds a dual Masters in Finance and Energy Systems from Columbia University and a Bachelor’s degree from Technical University

Lauren Li
Lauren Li
Head of Digital Health
Ipsen
Lauren Li
Head of Digital Health
Ipsen

Lauren Li is Head of Digital Health at Ipsen, a global biopharmaceutical group dedicated to improving lives through innovative medicines in Oncology, Neuroscience, and Rare Diseases. Driven by a passion to improve the access to and quality of care around the world, she works at the intersection of life sciences and technology, leading a team to create “beyond the drug” solutions. Prior to Ipsen, she held multiple biotech commercial roles at Amgen both in the U.S. and in Europe, spanning digital innovation, analytics & insights, marketing, and sales. Lauren also formerly led strategy and operations at Princess Margaret Cancer Centre – a top 5 academic cancer hospital in the world, consulted at McKinsey & Company, and ran a successful family business. She holds an M.B.A. from Harvard Business School and a B.A. with honors in economics from Princeton University.

Anand Iyer
Anand Iyer
Chief Strategy Officer
Welldoc
Anand Iyer
Chief Strategy Officer
Welldoc

Anand is a respected global digital health leader—most known for his insights on and experience with technology, strategy and regulatory policy. Anand has been instrumental in WellDoc’s success and the development of BlueStar®. Since joining WellDoc in 2008, he has held core leadership positions that included Chief Data Science Officer, President and Chief Operations Officer. He holds an MS and a PhD in electrical and computer engineering, and an MBA from Carnegie Mellon University.

Aaron Gani
Aaron Gani
Founder & Chief Executive Officer
BehaVR
Aaron Gani
Founder & Chief Executive Officer
BehaVR

Aaron Gani is the founder and CEO of BehaVR, LLC, creating digital therapeutics for behavioral health through the unmatched psychological power of Virtual Reality. Gani has been creating applications and experiences with technology throughout his career in healthcare and financial services, up to and including serving as Chief Technology Officer of Humana, a Fortune 50 managed care organization.

After a decade+ in healthcare leading technology development of population health, utilization management, disease management programs, pharmacy, primary care, urgent care, Health IT, and clinical analytics, and constantly working on ways to improve and empower consumer health with technology, data and analytics, Gani identified the crucial gap between knowledge, tools, and activation of healthy behavior, and believes Virtual Reality experiences can close that gap.

Gani is a founding member of the Strategic Advisory Board of the Digital Medicine (DiMe) Society, and a founding advisory board member of the International Virtual Reality Healthcare Association (IVRHA). Gani holds a Master’s in Predictive Analytics from Northwestern University, an MBA, General Management and Health Sector Management from Duke University’s Fuqua School of Business, and a BS in Management/CIS from the University of Louisville.

Debbie Lin
Debbie Lin
Executive Director
Boehringer Ingelheim Venture Fund
Debbie Lin
Executive Director
Boehringer Ingelheim Venture Fund

Dr. Debbie Lin is Executive Director at Boehringer Ingelheim Venture Fund in the US and leads the Fund’s North American efforts in Digital Healthcare.   She joined Boehringer Ingelheim Pharmaceuticals in 2008.  Within Boehringer Ingelheim Pharma, she worked across various regions and divisions.  She has worked in Medical Affairs in the area of women’s health and later in Health Economics and Outcomes supporting all commercial product sales with large payers and providers accounts on the West Coast.  She also led the US organization’s social entrepreneurship program in Boehringer Ingelheim’s Making More Health collaboration with Ashoka.  In 2013, she transitioned to Corporate Headquarters in Germany in Corporate Strategy and Development as Director of Corporate Development.  There she was responsible for BI’s global development strategy, leading BI’s global venture into stroke rehabilitation.  She led  multi-country teams to set up the company’s first stroke rehabilitation centers in Shanghai, China and in Lisbon, Portugal.  Prior to Boehringer Ingelheim, she worked as a Public Policy Consultant for Pacific Health Policy Group supporting Medicaid Policy implementation in various states such as Vermont and West Virginia during the Clinton Administration. Her doctorate is in Pharmacogenomics and Bioinformatics from UCSF, she also has a Masters in Engineering from Stanford University and a Masters in Public Policy from UCLA.   Debbie is a native Californian, she loves sunshine, being around nature and the ocean, yoga and dogs.

Ted James
Ted James
Chief, Breast Surgical Oncology & Director, Breast Care Center
Beth Israel Deaconess Medical Center
Ted James
Chief, Breast Surgical Oncology & Director, Breast Care Center
Beth Israel Deaconess Medical Center

Dr. James is the Chief of Breast Surgical Oncology, co-Director of the Breast Care Center, and Vice Chair of Academic Affairs in the Department of Surgery at Beth Israel Deaconess Medical Center. His research interests focus on improving the quality of breast cancer surgery through outcomes research and clinical innovations. Dr. James provides research mentoring opportunities to medical students and residents.

In addition to his clinical background, Dr. James obtained a master’s degree in health care management from the Harvard School of Public Health and addresses health systems and quality issues in clinical oncology. He serves in national leadership roles and has directed programs in quality improvement, clinical education and health services research. His mission is to improve patient care through research, education and innovation.

Jo Masterson
Jo Masterson
Chief Executive Officer
2Morrow, Inc.
Jo Masterson
Chief Executive Officer
2Morrow, Inc.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow’s evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past “40 under 40“ who started her career as a nurse and has worked in healthcare, education and technologies companies.

Joris van Dam
Joris van Dam
Executive Director, Head of Digital Therapeutics
Novartis
Joris van Dam
Executive Director, Head of Digital Therapeutics
Novartis

Joris van Dam is a Digital Health intrapreneur with 15 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of therapies in schizophrenia and multiple sclerosis.

Prior to that, Joris launched a number of digital health innovation initiatives at Novartis, including the launch of the Trials of the Future program, the Patients-2-Trials Consortium (a pharma consortium project to facilitate clinical research navigation for patients), the Clinical Research Collaboration with Walgreens (running interventional clinical trials at local Walgreens Healthcare clinics), TriNetX (a platform for using electronic medical records for study planning and design), CentrosHealth (a platform for patient engagement Apps in clinical trials), and a mobile platform for bedside data collection for clinical trials in Africa.

Prior to joining Novartis, Joris spent 7 years at Janssen, where a.o. he worked in partnership with the Bill and Melinda Gates Foundation to launch a mobile health platform for improving treatment of HIV patients in various regions across India, and led Janssen’s participation to the EHR4CR program at the EU’s Innovative Medicines Initiative (IMI). Prior to joining pharmaceutical research and development, Joris spent 7 years in consulting across industries and across Europe. Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

Acacia Parks
Acacia Parks
Chief Scientist
Happify Health
Acacia Parks
Chief Scientist
Happify Health

Dr. Parks’ research focuses on self-help methods for increasing well-being via books and digital technology. She is Chief Scientist for tech startup Happify, which brings the cutting edge in research-based well-being interventions to large businesses, health plans, and consumers. Her research spans across the whole spectrum of wellness, from non-distressed consumers to stressed employees, sufferers of chronic health conditions, and individuals with depression and/or anxiety. She works to pioneer new methodology in the study of digital therapeutics, especially when it comes to outcomes assessment. Her work has been published in peer-reviewed journals, and in addition to editing three books, she is also an Associate Editor at the Journal of Positive Psychology.

Kenichiro Nishii
Kenichiro Nishii
Lead, Regulatory Affairs & Business Development
CureApp
Kenichiro Nishii
Lead, Regulatory Affairs & Business Development
CureApp

Ken is a regulatory affairs and business development lead at CureApp North America. He is specialized in US regulatory compliance with a strong engineering background. Before joining CureApp, he worked for regulatory compliance and business consulting company where he completed more than 14 regulatory submissions ranging from De Novo and 510(k) to Q-subs (Pre-sub, submission issue, supplemental) and variance requests.

With a variety of regulatory submission experience for products from early to late stages of development, he is currently responsible for CureApp’s US regulatory compliance, acting as a vital liaison between Japanese and US regulatory agencies.

In Japan, CureApp recently completed a phase III clinical trial and regulatory submission to the Japanese PMDA for a smoking cessation app. CureApp would like to share insights from outside of the US regulatory environment at the DTx East meeting.

Jessica Lipschitz
Jessica Lipschitz
Associate Director, Digital Behavioural Health & Informatics Research Program
Brigham & Women’s Hospital
Jessica Lipschitz
Associate Director, Digital Behavioural Health & Informatics Research Program
Brigham & Women’s Hospital

Jessica M. Lipschitz, Ph.D. is the Associate Director of the Digital Behavioral Health & Informatics Research Program at Brigham and Women’s Hospital and is affiliated with Harvard Medical School. Her research focuses on evaluation and implementation of digital behavioral health tools, specifically patient/provider/systems-level engagement and use of these tools to inform precision medicine. Dr. Lipschitz has worked extensively with the VA on national digital health rollout initiatives and has consulted and conducted research in partnership with industry aimed at improving and implementing digital health solutions for behavioral health. She serves on the editorial board for JMIR – Mental Health.

Madhavi Jagdish
Madhavi Jagdish
Director, Product Design
Pear Therapeutics
Madhavi Jagdish
Director, Product Design
Pear Therapeutics

Madhavi Jagdish is the Director of Product Design at Pear Therapeutics, and has designed mobile applications for over a decade, both in the consumer space and now in this revolutionary field of prescription digital therapeutics. She is very excited about the possibility of design changing people’s lives in meaningful and long-lasting ways.

Chris Wasden
Chris Wasden
Head of HappifyDTx
Happify Health
Chris Wasden
Head of HappifyDTx
Happify Health

As Head of HappifyDTx and Board Member of the Digital Therapeutic Alliance (DTA), Chris is leading the effort to bring Happify’s platform to the pharmaceutical and healthcare industry. Recently he was a professor at the University of Utah and served as Executive Director of the Sorenson Center for Discovery & Innovation, a digital health game incubator. He is the co-author of two books on innovation, creativity, and leadership: Tension – The Energy of Innovation; and Solving for Why – Change Your Identity, Change Your Future. He is the named inventor on 12 issued patents, has been a founding leader in 10 startups, and has held leadership positions at JP Morgan and PwC. He holds a doctorate from George Washington University in Human and Organizational Learning, and an M.B.A. from UCLA Anderson School.

Sarah Jackson
Sarah Jackson
Chief of Staff
Click Therapeutics
Sarah Jackson
Chief of Staff
Click Therapeutics

Sarah Jackson is Chief of Staff at Click Therapeutics, where she operates across business development, alliance management and strategy. In her role, Sarah actively seeks partnership and licensing opportunities, supports deal execution, and manages collaboration relationships and operations. Sarah holds a B.A. cum laude in Cognitive Neuroscience and Evolutionary Psychology from Harvard College.

Chihiro Hosoya
Chihiro Hosoya
Head of Venture Management & Business Development, Rx+ Business Accelerator
Astellas Pharma
Chihiro Hosoya
Head of Venture Management & Business Development, Rx+ Business Accelerator
Astellas Pharma

Chihiro leads business development and manages relationship with partner venture capitals for Rx+ Business in Astellas. Rx+ is a concept of new healthcare solution created by combining innovative new technology in different field and Astellas capabilities developed in pharma business. In her role, Chihiro actively seeks partnership and investment opportunities in the growing field of Rx+ business, with high focus in digital health and medical device. Chihiro has 15 years of industry experiences in research and Business Development in addition to Rx+ business. She received an MSc from Waseda University and an MBA from Tsukuba University.

Matthew Tucker
Matthew Tucker
Executive Director, Strategy & Transformation
Highmark Health
Matthew Tucker
Executive Director, Strategy & Transformation
Highmark Health

Matthew Tucker helps healthcare companies solve complex commercial problems so they can grow bigger and faster. With extensive experience leading commercial planning and execution across functional areas, Mr. Tucker has leveraged his leadership roles at Highmark Health, Baxter, Mylan, and a number of startups. Over the course of his career, he has led significant growth in health plan initiatives and of more than 20 medical device and pharmaceutical brands.

Pablo Pantaleoni
Pablo Pantaleoni
Vice President & General Manager of Health
Headspace
Pablo Pantaleoni
Vice President & General Manager of Health
Headspace

Pablo is Vice President and General Manager at Headspace Health. He leads the newly formed digital therapeutics subsidiary that aims to develop digital therapeutic products to help mitigate and treat chronic health conditions. Pablo also co-leads the Digital Health NEXT Program at Stanford Biodesign.

Before joining Headspace, Pablo was the Senior Director of Health and Venture Design at IDEO. He partnered with startups and global corporations alike to develop digital products and services at the intersection of health and other industries, such as mobility, retail and education.

Pablo is an entrepreneur. He co-founded Medtep, a digital health startup with the aim to facilitate lasting behavioral changes by personalizing validated prevention and treatment plans. While in college, Pablo founded his first start-up, Apartyment. Now part of Grupo Avanzia, the company helps international students in Europe to find accommodation, internships, and languages courses. Earlier in his career, Pablo worked as an economist for banks and brokerage firms, specializing in international markets.

Pablo was selected in the Forbes’ ‘30 Under 30’ list in healthcare in 2016. He is also an Endeavor entrepreneur and has mentored several other startups. Pablo holds a Master’s degree in Business Administration Technology from the Ramon Llull University, and a Bachelor’s degree in Economics and Business Administration from Pompeu Fabra University, both in Barcelona.

Malinda Peeples
Malinda Peeples
Senior Vice President, Clinical Services, Programs & Research
Welldoc
Malinda Peeples
Senior Vice President, Clinical Services, Programs & Research
Welldoc

Malinda Peeples, MS, RN, CDE, FAADE is Senior Vice President of Clinical Services, Programs, and Research at WellDoc, a digital health company transforming the delivery of health care in the value-based world with the use of FDA-cleared digital health solutions focused on chronic disease care. In this role at WellDoc over the last decade Malinda has been a leader and champion in the digital health arena. She has been at the forefront of defining the digital health domain and remodeling how practitioners implement these clinically effective and cost containing innovative tools. By background Malinda is a registered nurse, certified diabetes educator and clinical and informatics nurse specialist.

Peeples earned a bachelor’s degree in nursing from the University of North Carolina in Charlotte, a master’s degree in nursing informatics from the University of Maryland School of Nursing (UMSON) in 1997, and a master’s degree in health sciences informatics from The Johns Hopkins School of Medicine in 2007. She currently serves as an Adjunct Assistant Faculty member in the Division of Healthcare Informatics at Johns Hopkins.

Malinda has been a dedicated volunteer for numerous local and national professional organizations. In 2005-2006 she served as President of the American Association of Diabetes Educators, an association that awarded the Distinguished Service Award to her in 2018. Currently Malinda is on the Maryland ADA Board of Directors and is on the University of Maryland at Baltimore Foundation Board of Trustees.

Brian Harris
Brian Harris
Chief Executive Officer
MedRhythms
Brian Harris
Chief Executive Officer
MedRhythms

Brian is the co-founder and CEO of MedRhythms, Inc, a digital therapeutics company that builds evidence-based neurologic interventions for acute and chronic neurological populations using music, AI, and sensors.. As a clinician, Brian became one of only 2e50 people world with advanced training in the neuroscience of music. Harris was hired as the first NMT at Spaulding Rehabilitation Hospital in Boston, where, in 2015, he founded the clinical division of MedRhythms

Seung Eun Choi
Seung Eun Choi
Chief Executive Officer
S-Alpha Therapeutics
Seung Eun Choi
Chief Executive Officer
S-Alpha Therapeutics
Derek Richards
Derek Richards
Chief Scientific Officer
SilverCloud Health
Derek Richards
Chief Scientific Officer
SilverCloud Health

As Chief Science Officer at SilverCloud health, Derek Richards is part of the executive team that decides on the strategic direction of the company and the execution of the strategic objectives for success. Over the past years, he has helped build a successful enterprise which gained significant market traction. Their success built on their robust empirical research base. As Chief Science Officer, Derek knows that a central aspect of where the organisation is going is the continued attention to research. They have a vigorous research strategy that supports the commercial strategy that they are committed to successfully realising.

As Director of the e-mental health group at the School of Psychology, Trinity College Dublin, Derek is involved in understanding how he and his team can leverage technologies to benefit mental health, health in general and our wellbeing. Digital health’s contribution to mental and behavioural healthcare has been significant, but they also know that we have most likely only begun to scratch the surface of the potential that current and emerging technologies can offer. It is a fascinating and innovative time for psychological science as it embraces technology to support the dissemination and greater access and reach to evidence-based treatments, preventative programmes and for the first time the potential to globalise these efforts. In collaboration with our partners, they are exploring many new avenues of implementation and research using online delivered interventions.

Eddie Martucci
Eddie Martucci
Chief Executive Officer
Akili Interactive
Eddie Martucci
Chief Executive Officer
Akili Interactive

Eddie is CEO/co-founder of Akili Interactive, a leading digital therapeutics company creating treatments for people living with cognitive impairments. Akili was founded on the belief that medicine should not just be safe and effective, but fun and engaging. Akili’s products are delivered through immersive action video game experiences and the company is working to transform the patient experience. Prior to starting Akili in 2011, Eddie co-founded two other health-focused start-ups and helped to launch PureTech Health’s DH initiative. He is a former Kauffman Entrepreneur Fellow, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry and received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University. Eddie frequently serves on discussion panels for industry and academic events and appears in top-tier media reports on healthcare innovation. Akili has received recognition including the 2014 Future of Health Tech product award, 2015 50-on-Fire Boston, #1 health company in Entrepreneur magazine’s 100 Brilliant Companies of 2016, CNS Summit 2017 Innovation Award winner, and finalist for 2018 Bostonfest Coolest Companies and 2018 Business Intelligence Best Places to Work.

Patty Scalzo
Patty Scalzo
Director, Diabetes Technology Initiatives
The Association of Diabetes Care & Education Specialists (ADCES)
Patty Scalzo
Director, Diabetes Technology Initiatives
The Association of Diabetes Care & Education Specialists (ADCES)

Patty Scalzo, MSN, NP, CDCES, is the Director of Diabetes Technology Initiatives at ADCES. In this role, she provides thought leadership, strategic direction and content expertise to ADCES’s Danatech platform and related resources. The Danatech platform was created to serve as the go to diabetes technology resource for the association membership of diabetes care and education specialists.

During her years at Mayo Clinic, Patty was co-recipient of an award through the Center for Innovation, to create a Diabetes Technology Clinic Remote Access program and to redesign the Diabetes Technology Clinic. Patty has experience in the medical device industry, digital health and clinical care.

Marisa Cruz
Marisa Cruz
Chief Medical Officer
Limbix
Marisa Cruz
Chief Medical Officer
Limbix

Dr. Marisa Cruz is the Chief Medical Officer for Limbix. She previously served as the Senior Medical Advisor for the Digital Health Unit in the Center for Devices and Radiological Health at the US Food and Drug Administration, providing leadership in the development and implementation of digital health policy for medical devices. Prior to joining CDRH, Marisa served as a senior advisor to the Associate Commissioner for Public Health Strategy and Analysis. She received her M.D. from the Johns Hopkins School of Medicine, completed an Internal Medicine residency and Endocrinology fellowship at the University of California, San Francisco, and continues to provide clinical care at George Washington University.

Burt Rosen
Burt Rosen
President
Society for Participatory Medicine
Burt Rosen
President
Society for Participatory Medicine

Burt Rosen oversees all Marketing for HealthSparq.  He is responsible for developing and telling HealthSparq’s story; what we do, who we do it for and how we do it. He is passionate about putting people at the center of health care and has launched efforts such as What’s the Fix? to put people back in the center of the conversation.

Prior to HealthSparq, Burt spent five years at Knowledge Universe, the leading provider of early childhood education in the US (KinderCare is their biggest brand). He started there as VP Digital and Customer Experience and eventually took on all of Marketing, from market and customer research, to creative, PR, acquisition and everything digital.

Before Knowledge Universe, Burt was at Starwood Hotels for 4 years leading a digital and call center strategy team that serviced each of Starwood’s 9 brands, and eventually leading all marketing for Starwood Preferred Guest, Starwood’s award winning loyalty program.

Burt has 6 years of experience working in Account Management at Avenue A/Razorfish and Modem Media and 12 years experience working in all facets of Television on the advertising sales side.

Elizabeth Gazda
Elizabeth Gazda
Chief Executive Officer
Embr Labs
Elizabeth Gazda
Chief Executive Officer
Embr Labs
Gregory Dodell
Gregory Dodell
President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease
The Mount Sinai Hospital
Gregory Dodell
President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease
The Mount Sinai Hospital

Gregory Dodell, MD FACE is a board-certified endocrinologist. He received his medical degree from Albany Medical College. He completed his internal medicine and endocrinology Fellowship at St. Luke’s-Roosevelt Hospital Center, affiliated with Columbia University. He is an Assistant Clinical Professor of Medicine, Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai. He is the President of Central Park Endocrinology, PC.

Matthias Zenker
Matthias Zenker
Partner
GAIA AG
Matthias Zenker
Partner
GAIA AG

Matthias is a physician by training and holds a medical doctorate degree from the University of Ulm, Germany. He has gained both inpatient and outpatient medical expertise in various healthcare systems around the world. Matthias joined GAIA 17 years ago and takes the responsibility for the national and international business development and licensing activities with payer and physician organisations as well as industry partners. And when not travelling the world for business, he travels the world for leisure.

Davina Pallone
Davina Pallone
Vice President, Product
Fruit Street
Davina Pallone
Vice President, Product
Fruit Street
Jonas Thinggaard
Jonas Thinggaard
Head of Technology Scouting and Incubation, Digital Therapeutics
Novo Nordisk
Jonas Thinggaard
Head of Technology Scouting and Incubation, Digital Therapeutics
Novo Nordisk
Yasodhara Paruchuru
Yasodhara Paruchuru
Vice President, Value & Access
Happify Health
Yasodhara Paruchuru
Vice President, Value & Access
Happify Health
Joanna Mitri
Joanna Mitri
Staff Physician / Instructor in Medicine
Joslin Diabetes Center / Harvard Medical School
Joanna Mitri
Staff Physician / Instructor in Medicine
Joslin Diabetes Center / Harvard Medical School

Joanna Mitri, MD, MS, is interested in lifestyle-based interventions and prevention and management of type 2 diabetes and cardiometabolic disease.

Dr. Mitri practiced in Southern Massachusetts for few years prior to joining Joslin Diabetes Center.  Her clinical practice focuses on type 2 diabetes, lipid disorders and cardiovascular risk reduction. Her research has focused on the effect of lifestyle-based interventions in diabetes.

Dr. Mitri has published in several peer review journals on this topic.

Michael Latauska
Michael Latauska
Director, Digital Health
Boehringer Ingelheim
Michael Latauska
Director, Digital Health
Boehringer Ingelheim
Jen Horonjeff
Jen Horonjeff
Founder & CEO
Savvy Cooperative
Jen Horonjeff
Founder & CEO
Savvy Cooperative

Jen Horonjeff, PhD, is the founder and CEO of Savvy Cooperative, the first and only patient-owned public benefit co-op that helps healthcare companies connect directly with diverse patients in order to get the insights they need to build better and more inclusive innovations. Jen was named one of the 50 Most Daring Entrepreneurs of 2018 by Entrepreneur Magazine, alongside the likes of Elon Musk, Chance the Rapper and Reese Witherspoon, for her application of the cooperative model. Savvy has additionally won seven awards, and has been featured in Fast Company and the Boston Globe. Jen grew up with juvenile idiopathic arthritis and survived a brain tumor as an adult. She is also a health outcomes researcher at Columbia University Medical Center, a human factors engineer, and an FDA Consumer Representative. Jen earned her Master’s in Ergonomics and Biomechanics and PhD in Environmental Medicine, both from New York University. Utilizing her unique perspective, Jen is a sought after thought leader on patient engagement around the globe. She strives to give patients a platform to have their voices and expertise be heard, included, and equitably valued–because the future of healthcare is co-designed with patients.
Connect

Vik Panda
Vik Panda
Managing Director, North America
Dreem
Vik Panda
Managing Director, North America
Dreem

Vik Panda is Dreem’s Managing Director for North America, where he spearheads the business across the healthcare industry and consumers. He launched Dreem 2 in the United States, which is a sleep solution that helps people improve the quality of their sleep through a wearable and coaching program. Dreem’s mission is to solve the world’s sleep problems and bring awareness to the importance of sleep. Before joining Dreem, Vik was VP of Marketing at Adherium, a digital therapeutic focused on asthma and COPD, where he launched a direct-to-consumer channel and developed the enterprise strategy. Prior to this, he was CEO at Findyr, an alternative data company, and Chief Marketing Officer at Fitocracy, a fitness social network and online coaching platform with more than 2 million users. Vik began his career in technology by pioneering solutions to help people get fit and healthy. He is a contributor to various outlets, including STAT, CNBC and MedCity News. He has a Master of Business Administration from INSEAD, a Bachelor of Arts and Master of Arts in Economics from New York University, and has completed the Chartered Financial Analyst program.

Martha Menard
Martha Menard
Senior Scientist
Embr Labs
Martha Menard
Senior Scientist
Embr Labs

Martha Menard is a research scientist with 15+ of experience designing and leading research and evaluation projects for businesses, nonprofits, and academic institutions, specializing in integrative and behavioral health. She has her PhD in Research, Statistics and Evaluation from the University of Virginia, as well as having run a successful private massage therapy practice for over a decade.

Caleb Winder
Caleb Winder
Managing Director
MemorialCare Innovation Fund
Caleb Winder
Managing Director
MemorialCare Innovation Fund

Mr. Winder has over 25 years of operating, startup, and investing experience in healthcare companies. He plays an instrumental role in sourcing and structuring deals and works closely with portfolio companies to form strategic partnerships and to develop scalable commercialization and marketing strategies. He is currently (or formerly) Board Director or Observer at Aileron Therapeutics (IPO), AristaMD, Aventura (acquired by Philips Medical), Ayogo Health, ClearDATA, Cleveland HeartLab (acquired by Quest Diagnostics) InfoBionic, Laudio, Molecular Templates (IPO), Oculus Health, ShapeUp (merged with Virgin Pulse, acquired by Marlin), Silvercloud Health, Saladax Biomedical, Twistle, MedVentive (acquired by McKesson), and WellDoc.

Prior to joining MCIF, Mr. Winder was (and remains) Managing Director at Excel Venture Management. Prior to Excel Venture, Mr. Winder was a Principal at Biotechonomy Ventures where he was involved in the founding of Synthetic Genomics, serving as the Director of Finance, and its investments in BioTrove (acquired by Life Technologies), BIOCIUS (acquired by Agilent Technologies), and Xcellerex (acquired by GE Healthcare).

Prior to becoming a venture capitalist, Mr. Winder was an award-winning sales and marketing executive at medical equipment and diagnostics companies, Midmark Corporation and MGC Diagnostics. He graduated magna cum laude with an MBA from Babson College, where he was a Fellow in the Center for Technology Enterprise. He received a BA in Biology with a minor in Economics from Colby College.

Zack Lynch
Zack Lynch
Managing Partner
JAZZ Venture Partners
Zack Lynch
Managing Partner
JAZZ Venture Partners

Zack Lynch is a Managing Partner and co-founder of JAZZ Venture Partners, a San Francisco-based early stage venture capital firm focused on investing in human performance technology. He is an entrepreneur and futurist who brings a rich understanding of the forces driving the convergence of digital technologies and neuroscience and how new products and services are emerging to unlock human potential across health, wellness, learning, training, sports, enterprise and entertainment. He is the author of the best selling book The Neuro Revolution: How Brain Science Is Changing our World (St. Martin’s Press) which takes a 50 year view on how neuroscience will transform human society. Zack loves to snow board and spend time with his wife and kids.

Kate Rosenbluth
Kate Rosenbluth
Founder & Chief Scientific Officer
Cala Health
Kate Rosenbluth
Founder & Chief Scientific Officer
Cala Health

Kate Rosenbluth is a Founder, Member of the Board of Directors, and Chief Scientific Officer at Cala Health. She has previously served as Chief Executive Officer and raised three rounds of financing totaling over $80M. She is an engineer and neuroscientist who previously worked on cutting edge neurotherapies at Stanford Biodesign, UCSF Neurosurgery, Brainlab, Autonomic Technologies and Genentech.

Shaheen Lakhan
Shaheen Lakhan
Vice President, Head of Research & Development / Neurology & Pain Management Consultant
The Learning Corp / Cambridge Health Alliance
Shaheen Lakhan
Vice President, Head of Research & Development / Neurology & Pain Management Consultant
The Learning Corp / Cambridge Health Alliance
Kirsten Engelhardt
Kirsten Engelhardt
Associate Director, Applied Innovation and Process Improvement
Otsuka Pharmaceuticals
Kirsten Engelhardt
Associate Director, Applied Innovation and Process Improvement
Otsuka Pharmaceuticals
Mette Dyhrberg
Mette Dyhrberg
Founder & Chief Executive Officer
Mymee
Mette Dyhrberg
Founder & Chief Executive Officer
Mymee

Mette Dyhrberg is a digital health innovator committed to improving the quality of life for those with chronic disease. She is the founder and CEO of Mymee, a digital program that is rethinking autoimmunity. The Mymee protocol eases the symptoms of autoimmune disease through data analytics and health coaching.  As an authority on autoimmune issues, Mette is a frequent speaker at industry events and conferences such as Stanford Medicine X and Exponential Medicine.

Mette holds MS in economics and is a certified health coach. An economist turned diagnostician, she’s the Sherlock Holmes of anamnestic data. She first entered the functional medicine arena in an attempt to tackle her own chronic health issues. In her early twenties, she became severely ill. For years, Mette battled an ever-expanding array of medical diagnoses ending up with six different autoimmune diseases simultaneously. Mette took matters into her own hands, hacked her own health and in doing so, she created a tool that solved her health problems and soon began helping others do the same.

Joe Perekupka
Joe Perekupka
Chief Commercial Officer
Palo Alto Health Sciences
Joe Perekupka
Chief Commercial Officer
Palo Alto Health Sciences

Joe is the Chief Commercial Officer for Palo Alto Health Sciences, a digital therapeutic company that is focused in the behavior health space. Freespira is an FDA-cleared treatment  has been proven to significantly reduce or eliminate symptoms for patients suffering from panic attacks, Panic Disorder or PTSD. Prior to joining PAHS, Joe was the GM/SVP of North America for another start-up company in the behavioral space, called Brainsway, leading the company to successful IPO in 2019. He has a strong background in various sales and leadership roles in healthcare companies including St Jude Medical and Bristol-Myers Squibb. He earned his a BA from Penn State University and an MBA from Fordham University.

Audrey Kern
Audrey Kern
Global Medical Director
Pear Therapeutics
Audrey Kern
Global Medical Director
Pear Therapeutics

Dr. Kern is board certified in Addiction Medicine by the American Board of Addiction Medicine. In addition, she has been board certified by the American Board of Emergency Medicine. She is currently Global Medical Director at Pear Therapeutics, serving as an expert in Substance Use Disorder and Opioid Use Disorder for the development of clinically validated software designed to provide better outcomes for patients through Prescription Digital Therapeutics (PDTs), software-based disease treatments for SUD and OUD which are tested for safety and efficacy in randomized clinical trials, authorized by the FDA and prescribed by healthcare providers.

In addition to this work, she maintains a clinical practice at Sobriety Centers of New Hampshire, Antrim New Hampshire, treating a rural population of outpatients receiving medically assisted treatment for addiction disorders at a residential treatment facility for women.

Dr. Kern is an active leader within the American Society of Addiction Medicine (ASAM) and is Immediate Past President of the Northern New England Society of Addiction Medicine, representing Maine, New Hampshire and Vermont. She has made significant contributions to the field of addiction medicine. As Medical Director for the Addiction Research Center at Dartmouth, Dr. Kern was a leader in the design and coordination of NIH and industry sponsored multi-center trials at Dartmouth Hitchcock Medical Center with clinic sites in New Hampshire and throughout the country, with a focus on increasing treatment options for alcoholism. During her tenure at the Addiction Treatment Program at Dartmouth, she was a collaborating physician in the Vermont Medication Assisted Treatment Learning Collaborative, helping to pioneer the Hub and Spoke model of addiction health care delivery. As a member of the Perinatal Treatment Program, she provided specialized treatment for pregnant and postpartum women with substance use disorders. She has served in multiple leadership roles including Medical Director for the State of Vermont Department of Corrections, providing leadership and oversight in healthcare services for all inmates in the State of Vermont, and is a Certified Correctional Health Professional. Other roles have included Medical Director for Health Care Resource Centers, methadone treatment programs in New Hampshire, and the Road to a Better Life programs providing evaluation, coordination and ongoing care for addictions patients outpatient-based opioid treatment.

Dr. Kern earned her Medical Degree from New York Medical College in Valhalla NY and completed her Emergency Medicine residency at Albany Medical Center in Albany NY. She was the recipient of the Air Force Health Professions Scholarship and served in the United States Air Force from 1985 through 1997. She served as an Emergency Physician at Malcolm Grow Medical Center, Andrew Air Force Base, Washington D.C. and later at Walter Reed Army Hospital, and was a Clinical Instructor at the Uniformed Service University of Health Services in Bethesda, MD. She received the United States Air Force Medal for Meritorious Service.

Dr. Kern was awarded an Osherson Fellowship at the Alonso Center for Psychodynamics at the Fielding Graduate University in Santa Barbara, CA, where she completed a fellowship in 2013 with a study focus on psychodynamic research, theory and clinical application to the field of addictions.

Peter Hames
Peter Hames
Chief Executive Officer
Big Health
Peter Hames
Chief Executive Officer
Big Health
Paul Upham
Paul Upham
Head, Smart Devices
Roche / Genentech
Paul Upham
Head, Smart Devices
Roche / Genentech

Paul is a Senior Principal at Roche / Genentech where he leads the Smart Device Technology Center. Paul has 20 years of experience in medical device R&D, strategic marketing, product management, clinical research, and medical informatics.

Prior to Roche / Genentech, Paul was with Becton Dickinson(BD), as Worldwide Director of Strategic Marketing in their Pharmaceutical Systems business. Paul and his team were responsible for all upstream and downstream marketing strategy for BD’s self-injection business, including pen injectors, autoinjectors, and wearable patch injectors.

Prior to that role, Paul was with WellDoc, Inc as Director of Product Marketing, where he built and led the marketing team and was responsible for product management activities for WellDoc’s portfolio of mobile health solutions. He was also the Core Team Leader for WellDoc’s landmark BlueStar™ product, a class II medical device and the world’s first reimbursed, prescription-only software for type 2 diabetes.

Paul’s prior experience includes 10 years at BD in the Diabetes Care business. Paul was responsible for the development and launch of the award-winning BD InterActiv® Diabetes Software, and was a member of the joint BD / Medtronic core team that launched ParadigmLink®, the world’s first wireless blood glucose meter.

Paul holds an issued patent in medical software and numerous patent applications covering software and medical devices. He is also an author and co-author of numerous peer-reviewed articles in medical informatics and in diabetes. His education background includes undergraduate studies in cognitive science and graduate work in health informatics and finance at the University of Minnesota and New York University.

April Scott
April Scott
Senior Director, Patient Support Services
Akili Interactive
April Scott
Senior Director, Patient Support Services
Akili Interactive

April Scott is Head of Patient Support at Akili Interactive. In this role, she is responsible for building and leading Akili’s personalized customer support services, Akili Assist.

Akili Assist strives to build meaningful and personalized relationships with every patient and their care teams however it’s easiest for them — by phone, via chat, text, or email. Akili Assist is the engine that enables Akili to do this by wrapping the care team around the patient experience.

Previously, April was the Director of Reimbursement Strategy and Patient Access at Otsuka America Pharmaceuticals where she provided oversight and strategic vision for the ASSURE Patient Support Center and the Otsuka Patient Assistance Foundation supporting multiple CNS and renal therapies. Specifically, April focused on transitioning the programs from traditional cookie-cutter solutions to those that met patients’ needs based on their individual journeys. Additionally, April was the Director of Assistance Programs at Mallinckrodt Pharmaceutical Inc.

Alex Waldron
Alex Waldron
Chief Strategy Officer
Pear Therapeutics
Alex Waldron
Chief Strategy Officer
Pear Therapeutics

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations.

He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals.

Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Scott Kellogg
Scott Kellogg
Senior Vice President, Regulatory Affairs, Quality Assurance, GMP & Clinical Operations
Akili Interactive
Scott Kellogg
Senior Vice President, Regulatory Affairs, Quality Assurance, GMP & Clinical Operations
Akili Interactive

Mr. Kellogg has worked in the medical device life-science industry for over 27 years and is currently the SVP in charge of medical devices (including RA, QA, GMP, and Clin Ops) at Akili Interactive Labs, Inc. Prior to joining Akili, Mr. Kellogg was an integral member of the founding teams at Follica Bio, Afferent, Corp., Sontra Medical, Inc., and UltraCision, Inc., where he served as the Vice President of Business Operations, Vice President of Product Development, Vice President of R&D, and Director of Engineering, respectively.

In these leadership roles, Mr. Kellogg was focused on commercializing novel medical technology. The technologies included digital therapy, surgical modalities, transdermal analyte detection, point-of-care diagnostics, transdermal drug delivery, neuro-stimulation, and therapeutic drug/device combinations. Additionally, he served in lead project management roles at Mentor Medical, Inc. and Ethicon Endo-Surgery, Inc (J&J). His broad experience includes product development/engineering, regulatory strategy/oversight, clinical design/operations, GMP & QSR establishment/compliance, intellectual property, and business development/strategic partnerships.

Mr. Kellogg graduated with high honors from the University of Massachusetts at Amherst with a BS in Engineering and received his MS and MBA from Northeastern University. He is an inventor on many domestic and international patents and the lead inventor on key patents for the Harmonic Scalpel ($1B/year product). In 2004 he and his team were awarded Popular Science’s “Best of what’s new in health care.”

Rachel Sha
Rachel Sha
Vice President, Digital Business Development
Sanofi
Rachel Sha
Vice President, Digital Business Development
Sanofi

Rachel Sha is the Vice President of Digital Business Development & Licensing at Sanofi.  She leads a team of

business development professionals in partnering, from identification to closing, across therapeutic areas and use cases in digital health with the goal of discovering, developing, and bringing to market solutions that improve outcomes, experience, at reduced costs.  Companies she has led partnering deals with in digital include Verily Life Sciences, Science 37, and Evidation Health.  Additionally, she serves on the Life Sciences Council of Springboard Enterprises which is focused on supporting women-led companies to grow and expand.

She joined Genzyme in 2005 and has held roles of increasing responsibility in Business Development, Corporate Development, and Global Marketing & Strategy for Genzyme and Sanofi.   Prior to Sanofi, Genzyme, Rachel was a manager at Accenture where she focused on a broad range of business issues from strategy to process to technology implementation.  Rachel holds a BS from Massachusetts Institute of Technology in Chemistry and an MBA from Harvard Business School.

Megan Coder
Megan Coder
Executive Director
Digital Therapeutics Alliance
Megan Coder
Executive Director
Digital Therapeutics Alliance

Megan Coder, PharmD, MBA, is Executive Director of the Digital Therapeutics Alliance. DTA’s mission is to broaden the understanding, adoption, and integration of clinically-evaluated digital therapeutics into mainstream healthcare through education, advocacy, and research.

With more than a decade of experience in the healthcare industry, Megan’s expertise extends from strategic growth and partnership development within the digital health sector, to the direct delivery of patient care. Prior to joining DTA, Megan worked with Voluntis, Iodine, the Pharmaceutical Care Management Association, and the Pharmacy Technician Certification Board.

A proud Badger, Megan graduated from the University of Wisconsin—Madison School of Pharmacy and completed an Executive Residency in Association Management & Leadership with the American Pharmacists Association.

James Karl
James Karl
National Account Manager
GSK
James Karl
National Account Manager
GSK
Rochelle Porper
Rochelle Porper
Vice President, Business Development
Palo Alto Health Sciences
Rochelle Porper
Vice President, Business Development
Palo Alto Health Sciences

Rochelle is VP, Client Success at Palo Alto Health Sciences, which offers Freespira, an FDA-cleared home-based and medication-free treatment that significantly reduces or eliminates symptoms of panic attacks, Panic Disorder and PTSD. Rochelle has decades of healthcare experience in a variety of roles including management consulting, health plan and employer sales, customer success, and marketing. Prior to joining the PAHS team, she worked for Best Doctors, Anthem, Towers Watson, Matria and NaviMedix. Rochelle received a Bachelor of Science degree from Kalamazoo College and a Masters in Social Work from the University of Michigan.

Andy Blackwell
Andy Blackwell
Chief Scientific Officer
IESO Digital Health
Andy Blackwell
Chief Scientific Officer
IESO Digital Health

Andy gained his doctorate in psychology from the University of St Andrews before working as a medical research scientist in world-leading laboratories in the departments of psychiatry and experimental psychology at the University of Cambridge.

In 2006 he became Chief Scientific Officer of Cambridge Cognition, a psychology and technology-focused business, and a year later joined the company board. He was part of the team that developed the commercial strategy that built the company up to a successful public listing on the AIM market in 2013.

At Ieso Digital Health Andy’s principle role is to develop and implement a global science and technology strategy to complement the commercial vision of the company.

Chris Lento
Chris Lento
Head, Healthcare Partnerships
Noom
Chris Lento
Head, Healthcare Partnerships
Noom
Lindsey Miller
Lindsey Miller
Development Associate
The Accelerated Cure Project for MS
Lindsey Miller
Development Associate
The Accelerated Cure Project for MS

Lindsey Miller Santiago was born, raised, and currently lives in the Boston, MA area with her husband and 4-year-old son. She graduated from Babson College with a degree in marketing and entrepreneurship and started at ACP as a development associate in the summer of 2012. Her mission is to see a cure for MS in her lifetime, and believes that it will be possible because of the work ACP is doing!

Andy Molnar
Andy Molnar
Vice President, Market Access
Cognoa
Andy Molnar
Vice President, Market Access
Cognoa
Jeffrey Abraham
Jeffrey Abraham
Vice President, Market Access & Trade
Akili Interactive
Jeffrey Abraham
Vice President, Market Access & Trade
Akili Interactive

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.

Melinda Decker
Melinda Decker
Chief Commercial Officer
Mymee
Melinda Decker
Chief Commercial Officer
Mymee

Melinda Decker is Chief Commercial Officer of Mymee, Inc., a digital care company that empowers those who suffer from autoimmune disease to reclaim their health.  Mymee combines an intuitive mobile app, data analytics, and certified health coaches to help identify triggers for disease symptoms, including diet and environmental factors, to improve the quality of life for those living with autoimmune diseases, like Lupus, Rheumatoid Arthritis and Crohn’s.  Mymee currently offers it’s program directly to individuals, as well as to large self-insured employers and health plans.

Melinda also serves as an advisor to MIT’s Health Science & Technology program and to several companies focused on digital health. She previously held leadership roles at AstraZeneca and Pfizer, spanning commercial and R&D.  Melinda holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.

Amir Lahav
Amir Lahav
Executive Director, Head of Digital Medicine
Karyopharm Therapeutics
Amir Lahav
Executive Director, Head of Digital Medicine
Karyopharm Therapeutics

Amir is an established neuroscientist specialized in digital medicine and clinical innovation. His strategic vision is empowered by real-world data that enable the discovery of clinical insights otherwise not possible solely based on conventional health records. Amir has boundless passion for accelerating novel therapies and creating a path for better patient experience. He brings an entrepreneurial zeal to the clinical world through disruptive technology and AI analytics from proof of concepts to scale-up solutions. Prior to pharma , Amir was a professor of Pediatrics and Epidemiology at Harvard Medical School and Harvard School of Public Health and served as a PI on numerous clinical trials with 200+ publications and conference presentations.

Owen McCarthy
Owen McCarthy
Co-Founder & President
MedRhythms
Owen McCarthy
Co-Founder & President
MedRhythms

Owen is the co-founder and President of MedRhythms Inc., a digital therapeutics company that builds evidence-based neurologic interventions for acute and chronic neurological populations using music, AI, and sensors. He is determined to provide patients across the globe with the services necessary to recover their walking ability and regain their independence. Owen started MedRhythms as an experienced entrepreneur with an MBA degree from Harvard Business School.

Workshops: Wednesday, September 16th
  • Workshop 1: The Business of Digital Therapeutics
  • Workshop 2: The Regulatory Masterclass
Workshop 1: The Business of Digital Therapeutics
The Business of Digital Therapeutics

This virtual workshop will enable you to deep-dive into the various commercial opportunities for Digital Therapeutics through a mix of learning formats. Get hands-on, hear from experts, share your thoughts and learn from your fellow attendees, this workshop will ensure that you leave with a deeper understanding of the business of Digital Therapeutics.

Workshop Leaders

Chris Wasden, Head of HappifyDTx, Happify Health

Mette Dyhrberg, Founder & Chief Executive Officer, Mymee

Pablo Pantaleoni, Vice President & General Manager of Health, Headspace

9:00 am
Presentation: An Inside Look at the Business of Digital Therapeutics
  • A brief overview of the various business models adopted by digital therapeutic companies
  • Where can we see commercial success in the industry so far?
  • When should digital therapeutics companies begin searching for reimbursement opportunities and who can offer them these opportunities?
9:30 am
Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the business of digital therapeutics and hear views on how best to successfully run a business in the DTx industry. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • What are the current business models being used within the industry and which are demonstrating the most success?
  • How do some business models favor certain types of digital therapeutic over others?
  • Can pharma help provide effective and recurring reimbursement for digital therapeutics
  • What can we learn from other areas of digital health?
10:30 am
Life Admin Break
11:00 am
Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members will be raised, via interactive polls, during this collaborative discussion.

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:

  • A deeper understanding of the various business models demonstrated by digital therapeutic companies
  • Up-to-date information on business models of varying successes in the current industry
  • A clear understanding of current routes to market and their intricacies
  • Robust knowledge on how the current commercial landscape impacts your work in this space
  • Your questions answered by industry leaders and your peers
12:00 pm
End of Workshop 1
Download Full Agenda
Workshop 2: The Regulatory Masterclass
The Regulatory Masterclass

This virtual workshop will enable you to deep-dive into Digital Therapeutics / Digital Health regulation through a mix of learning formats. Get hands-on, hear from experts, share your thoughts and learn from your fellow attendees, this workshop will ensure that you leave with a deeper understanding of the regulatory landscape.

Workshop Leader 

Scott Kellogg, Senior Vice President, Regulatory Affairs, Quality Assurance, GMP & Clinical Operations, Akili Interactive

2:00 pm
Presentation: An Introduction into DTx Regulation
  • A look at the different levels of regulatory approval available for digital therapeutics
  • Who can the digital therapeutics industry work with to begin and obtain regulatory approval?
  • How can digital therapeutics companies best work with regulators for mutual success?
2:30 pm
Breakout Discussions

Splitting into smaller groups, you will discuss the intricacies of the regulatory process for digital therapeutics. Make notes on the virtual platform for all members of the group to contribute to, on the following:

  • What are the different levels of regulatory approval for DTx and how are they defined?
  • How can we best work with the FDA to speed up the regulatory process and ensure both entities are on the same page?
  • How can we learn from others’ successes and failures to ensure we are moving forward as an industry?
  • What impact is the FDA Pre-Cert program having on digital therapeutics?
  • Where should digital therapeutics be focusing clinically for FDA regulatory approval?
3:30 pm
Life Admin Break
4:00 pm
Feedback Session

Representative(s) from each group will be invited onto the virtual “stage” to share the main points from their discussion to the whole group. Additional questions from moderators and other group members, via interactive polls, will be raised during this collaborative discussion.

Summary thoughts will then be shared by the moderator(s) and all participants will leave with the below:

Leave this workshop with:

  • A clear understanding of how digital therapeutics can obtain regulatory approval
  • What claims you can make for each level of regulation
  • An understanding of current FDA clinical trial guidelines in the space
  • What regulators want and need to see from digital therapeutics for successful regulatory approval
  • Your questions answered by industry-leading experts and your peers
5:00 pm
Close of Workshop 2
Download Full Agenda

Main Conference Agenda

  • Throughout Conference
  • Day 2: Thursday, September 17th
  • Day 3: Friday, September 18th
Throughout Conference
Networking Available All Day
  • 9:00am – 6:00pm – Day 2, Thursday, September 17th

  • 9:00am – 1:00pm – Day 3, Friday, September 18th

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

  • See who’s in the room – you will be able to message all live attendees and connect with those who respond.
  • Schedule 1-2-1 video calls with your connections at any time that suits you.
  • Open Networking – think of this as the event lobby where you can replicate those all-important “water-cooler” moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

On-Demand Content Available All Day
  • 9:00am – 6:00pm – Day 2, Thursday, September 17th

  • 9:00am – 1:00pm – Day 3, Friday, September 18th

DTx East is bursting at the seams with interactive, live content but there are also pre-recorded sessions from more industry-leaders that you can view at your leisure.

These recordings will be available throughout the day, ensuring that you don’t miss any sessions that you want to view or take part in that are happening in real-time.

Download Full Agenda
Day 2: Thursday, September 17th

Location: Stage

9:00am
Chair’s Opening Remarks
  • How has the Digital Therapeutics industry progressed since DTx West 2020?
  • What should we expect to have learned by the end of DTx East 2020?

Matthew Tucker, Executive Director, Strategy & Transformation, Highmark Health

9:05am
Presentation: Innovative Partnerships, Driving Patient Outcomes and Value
  • Why does digital/pharma/device partnerships make sense?
  • Share with the audience vision/mission behind our partnership – Why working together is best for patients
  • What were the opportunities/challenges we faced while scaling this partnership?
  • What does success look like, what are the long term goals for this partnership?

Chris Lento, Head, Healthcare Partnerships, Noom

9:30am
Wellness Break

Get-up and have a stretch before the next session begins.

9:35am
Panel Discussion & Interactive Q&A: Digital Therapeutics in the Covid-19-Impacted Healthcare System

In just a few months, huge disruption has occurred to healthcare systems across the world as a result of Covid-19. Digital therapeutics are uniquely positioned to deliver for patients with unmet medical needs where more traditional methods may now not be fit for purpose. Hear from industry leaders on how their organizations have adapted to new opportunities. Hear the experts’ thoughts on:

  • How has Covid-19 changed our belief in what digital therapeutics can do for patients?
  • What opportunities have opened up due to the recent changes in healthcare systems?
  • How have payers adapted their thoughts on digital therapeutics in this new age?
  • How can we better work with patients to ensure their new behaviors are factored into our products?
  • What more can we do as an industry to ensure digital therapeutics fill the gaps in healthcare where non-digital methods have previously fallen short?

 

David Klein, Chief Executive Officer, Click Therapeutics

Liz Kwo, Medical Director, Digital Health, Anthem

Eddie Martucci, Chief Executive Officer, Akili Interactive

Representative from Simon Kucher & Partners

Peter Hames, Chief Executive Officer, Big Health

10:05am
Life Admin Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.

10:05am
Open Q&A with Speakers

Location: Sessions

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

 

David Klein, Chief Executive Officer, Click Therapeutics

Liz Kwo, Medical Director, Digital Health, Anthem

Eddie Martucci, Chief Executive Officer, Akili Interactive

Representative from Simon Kucher & Partners

Peter Hames, Chief Executive Officer, Big Health

10:25am
Speed Networking

Location: Networking Area

 

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

DTx East Virtual will now split into two tracks

Personalize your experience by hopping in and out of sessions and meetings seamlessly, view on-demand content, or spend time in the Networking area.

Location: Stage

11:05am
Presentation by IQVIA

Representative from IQVIA

11:30am
Wellness Break

Get-up and have a stretch before the next session begins.

11:35am
Presentation: The Patient Perspective in Digital Therapeutics
  • What do patients really think of digital therapeutics?
  • An insight into the process of a patient using digital therapeutics over traditional drugs
  • Where can digital therapeutics improve to improve patient engagement, effectiveness and experience?

 

Burt Rosen, Former President, Society for Participatory Medicine

Jen Horonjeff, Founder & Chief Executive Officer, Savvy Cooperative

12:00pm
Wellness Break

Get-up and have a stretch before the next session begins.

12:05pm
Panel Discussion: Going Digital? - Digital Therapeutic Clinical Trials

Clinical trials are notoriously expensive and drawn out. In the theme of going digital, DTx companies are beginning to turn to online clinical trials. Hear from the experts who are leading the charge. Hear the experts’ thoughts on:

  • What are the benefits of virtual clinical trials for digital therapeutics over traditional trials
  • Are the results we’ve seen from virtual clinical trials as good and robust as traditional trials?
  • What do payers think of this new and novel approach for clinical data?
  • What are the drawbacks of virtual clinical trials compared with traditional trials?
  • How do regulators view virtual clinical trials for digital therapeutics?

 

Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc

Derek Richards, Chief Scientific Officer, SilverCloud Health

Shaheen Lakhan, Vice President, Head of R&D / Neurology & Pain Management Consultant, The Learning Corp / Cambridge Health Alliance

Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health

Kirsten Engelhardt, Associate Director, Applied Innovation and Process Improvement, Otsuka Pharmaceuticals

12:35pm-2:00pm
Lunch

Finally, a lunch at a conference that is completely your choice!

 

Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.

Location: Sessions

11:05am
Interactive Roundtable: Unravelling Digital Therapeutics Regulation - What it Means for You

This interactive, discussion-led session will enable you to deepen your understanding of Digital Therapeutics regulation. Share your insights, pose your questions to the group or simply listen in to the conversation, the choice is yours. Kickstarter discussions include:

  • A discussion on what evidence is required for FDA approval and what payers and clinicians want to see
  • What has been the impact of the FDA Pre-Cert program on digital therapeutics?
  • Understanding where best to prioritise clinical efforts in relation to regulatory approval

Actively or passively take part in this discussion.

 

Marisa Cruz, Chief Medical Officer, Limbix

Acacia Parks, Chief Scientist, Happify Health

Kenichiro Nishii, Lead, Regulatory Affairs & BD, CureApp

11:45am
Wellness Break

Get-up and have a stretch before the next session begins.

11:50am
Interactive Roundtable: Pharma-DTx Partnerships

This interactive, discussion-led session will enable you to deepen your understanding of Pharma-DTx partnerships. Share your insight, pose your questions to the group or simply listen in to the conversation, the choice is yours. Kickstarter discussions include:

  • What have we learnt from the recent partnership break-ups?
  • How have Pharma’s views on digital therapeutics changed over the last few months?
  • Do digital therapeutics companies need to present their value differently compared to pre-Covid-19?

Actively or passively take part in this discussion.

 

Melinda Decker, Chief Commercial Officer, Mymee

Amir Lahav, Executive Director, Head of Digital Medicine, Karyopharm Therapeutics

12:25pm
Wellness Break

Get-up and have a stretch before the next session begins.

12:35pm-12:55pm
Open Q&A with Speakers

Actively or passively take part in this discussion.

 

Malinda Peeples, Senior Vice President, Clinical Services, Programs & Research, Welldoc

Derek Richards, Chief Scientific Officer, SilverCloud Health

Shaheen Lakhan, Vice President, Head of R&D / Neurology & Pain Management Consultant, The Learning Corp / Cambridge Health Alliance

Kate Rosenbluth, Founder & Chief Scientific Officer, Cala Health

Kirsten Engelhardt, Associate Director, Applied Innovation and Process Improvement, Otsuka Pharmaceuticals

Day 2 of DTx East includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.
2:00pm
Tour of Expo

Location: Expo Area

Take a tour of the virtual Expo and interact with partners of DTx East to understand more about their services.

Location: Stage

2:20pm
Presentation by Biorasi

Representative from Biorasi

2:45pm
Wellness Break

Get-up and have a stretch before the next session begins.

2:50pm
Presentation: Offering Combined Therapies: Digital Health & Over-the-counter (OTC) Medicines
  • A case study looking at how 2Morrow partnered with GSK to offer a combined behavioral and pharmaceutical treatment for nicotine addiction
  • Lessons learned from 3 years of real-world experience offering digital behavioral therapy combined with over the counter (OTC) Nicotine Replacement Therapy to address nicotine addiction via employer wellness and population health channels

 

Jo Masterson, Chief Executive Officer, 2Morrow Inc

James Karl, National Account Manager, GSK

3:15pm
Wellness Break

Get-up and have a stretch before the next session begins.

3:20pm
Panel Discussion: Building a Healthcare Ecosystem for Digital Therapeutics Adoption

As digital therapeutics continue to race into the market, having a cohesive and streamlined workflow to enable HCP’s to administer these products remains a major goal of the industry. This panel will showcase the perspective from different players from across healthcare. Hear the experts’ thoughts on:

  • How are clinicians and healthcare providers viewing digital therapeutics?
  • How should digital therapeutic companies work together to build the infrastructure that will get these products to patients?
  • What are the key questions that providers have when digital therapeutic companies approach them?
  • What does the ideal infrastructure for getting digital therapeutics to patients look like?
  • Should digital therapeutic companies be exploring a “digital pharmacy”-type system?

 

Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital

Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)

Audrey Kern, Global Medical Director, Pear Therapeutics

Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences

3:50pm
Life Admin Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.

Location: Sessions

2:20pm
Interactive Roundtable: Digital Therapeutics & Telehealth

This interactive, discussion-led session will enable you to deepen your understanding of the interplay between Digital Therapeutics and Telehealth. Share your insight, pose your questions to the group or simply listen in to the conversation, the choice is yours. Kickstarter discussions include:

  • How has healthcare delivery changed over the past few months?
  • How have the recent changes opened up more opportunities for digital therapeutics?
  • How should digital therapeutics companies work with telehealth providers to get these products into the hands of more patients in need?

Actively or passively take part in this discussion.

 

Jeffrey Abraham, Vice President, Market Access & Trade, Akili Interactive

3:00pm
Wellness Break

Get-up and have a stretch before the next session begins.

3:05pm
Interactive Roundtable: Patient-centric Development for, Patient Engagement, Adherence and Clinical Outcomes

This interactive, discussion-led session will enable you to deepen your understanding of patients, in the context of digital therapeutics. Share your insight, pose your questions to the group or simply listen in to the conversation, the choice is yours. Kickstarter discussions include:

  • How can we best design digital therapeutics to keep patients engaged from the start?
  • When do conversations with patients need to start in the development process?
  • How can we marry the worlds of real-world research and product development?

Actively or passively take part in this discussion.

 

Davina Pallone, Vice President, Product, Fruit Street

Chris Wasden, Head of HappifyDTx, Happify Health

Jessica Lipschitz, Associate Director, Digital Behavioural Health & Informatics Research Program, Brigham & Women’s Hospital

Madhavi Jagdish, Director, Product Design, Pear Therapeutics

3:45pm
Wellness Break

Get-up and have a stretch before the next session begins.

3:50pm
Open Q&A with Speakers

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

 

Gregory Dodell, President of Central Park Endocrinology, Assistant Clinical Professor of Endocrinology, Diabetes and Bone Disease, The Mount Sinai Hospital

Patty Scalzo, Director, Diabetes Technology Initiatives, The Association of Diabetes Care & Education Specialists (ADCES)

Audrey Kern, Global Medical Director, Pear Therapeutics

Joe Perekupka, Chief Commercial Officer, Palo Alto Health Sciences

Location: Stage

4:10pm
Presentation: Using Real-World Data to Decode “What Works” in Digital Care Delivery

Andy Blackwell, Chief Scientific Officer, IESO Digital Health

4:35pm
Presentation by EVERSANA

Representative from EVERSANA

5:00pm
Wellness Break

Get-up and have a stretch before the next session begins.

5:05pm
Panel Discussion: What is the True Value of Digital Therapeutics?

Digital therapeutics have demonstrated how their mobility, flexibility and clinical effectiveness can offer huge value to a number of disease areas. However, we are yet to see a large uptake in DTx reimbursement and patient usage. This panel will investigate where the true value of digital therapeutics lie and opportunities available to maximize the value of DTx. Hear the experts’ thoughts on:

  • Where does the true “value” of digital therapeutics lie?
  • How does this value change based on the new Covid-19-impacted healthcare systems we find ourselves in?
  • With a huge increase in the demote for remote digital care, how does this impact the value of digital therapeutics?
  • Does this open up new reimbursement opportunities outside of the ones we have been previously exploring?
  • Will DTx/Drug combination therapies open up more commercialization and reimbursement opportunities for the industry?

Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk

Yasodhara Paruchuru, Vice President, Value & Access, Happify Health

Konstantin Mehl, Founder & President, Kaia Health

Alex Waldron, Chief Strategy Officer, Pear Therapeutics

Megan Coder, Executive Director, Digital Therapeutics Alliance

5:35pm - 6:35pm
Virtual Drinks

Location: Networking & Sessions

 

Share a virtual drink with old friends or new connections. At small virtual tables, this is your chance to casually interact with the rest of the Digital Therapeutics industry.

5:35pm - 6:00pm
Open Q&A with Speakers

Location: Sessions

 

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

 

Jonas Thinggaard, Head of Technology Scouting and Incubation, Digital Therapeutics, Novo Nordisk

Yasodhara Paruchuru, Vice President, Value & Access, Happify Health

Konstantin Mehl, Founder & President, Kaia Health

Alex Waldron, Chief Strategy Officer, Pear Therapeutics

Megan Coder, Executive Director, Digital Therapeutics Alliance

Download Full Agenda
Day 3: Friday, September 18th

Location: Stage

9:00am
Chairs Opening Remarks
  • Recap of Day 2 – what lessons have been learned already and what discussions stood out?
  • A look ahead at Day 3 – what can we expect to learn today?

Sarah Jackson, Chief of Staff, Click Therapeutics

9:05am
Panel Discussion: How Should Digital Therapeutics be Impacting the Lives of Patients?

Digital therapeutics have a huge opportunity to deliver for patients with unmet medical needs in a wide range of health conditions, particularly in the Covid-19-impacted healthcare systems we find ourselves in. However, crucial questions must be asked to ensure that these products truly deliver for patients. Hear the experts’ thoughts on:

  • As we stand today, what are digital therapeutics doing for patients?
  • In what areas can digital go above and beyond traditional therapeutics?
  • What is going to stop digital therapeutics from reaching their full potential?
  • What areas of success in the wider digital health landscape can we learn from when attempting to demonstrate the value of digital therapeutics?
  • How can we work closer with patients to ensure further adoption of digital therapeutics?

 

Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School

Anand Iyer, Chief Strategy Officer, Welldoc

Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center

April Scott, Senior Director, Patient Support Services, Akili Interactive

Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences

Lindsey Miller, Development Associate, The Accelerated Cure Project for MS

9:35am
Life Admin Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.

9:35am
Open Q&A with Speakers

Location: Sessions

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

 

Joanna Mitri, Staff Physician / Instructor in Medicine, Joslin Diabetes Center / Harvard Medical School

Anand Iyer, Chief Strategy Officer, Welldoc

Ted James, Chief, Breast Surgical Oncology & Director, Breast Care Center, Beth Israel Deaconess Medical Center

April Scott, Senior Director, Patient Support Services, Akili Interactive 

Rochelle Porper, Vice President, Business Development, Palo Alto Health Sciences

Lindsey Miller, Development Associate, The Accelerated Cure Project for MS

9:55am
Panel Discussion: What do Pharma Really Think of Digital Therapeutics?

Location: Stage

Answering the age-old question to truly identify what pharma thinks of digital therapeutics. In recent months, there has been a smattering of both partnerships and breakups between pharma and DTx companies. This panel, stacked with pharma leaders, will deep-dive into the pharmaceutical perspective of digital therapeutics. Hear the experts’ thoughts on:

  • From a pharma perspective, what is the true value of digital therapeutics?
  • How has the impact of Covid-19 changed your view on the potential of digital therapeutics?
  • What have we learned from both the more and less successful pharma partnerships?
  • Does there need to be a new approach taken to ensure successful partnerships in the future?
  • How can both DTx companies and pharma companies ensure successful and mutually beneficial partnerships?

 

Michael Latauska, Director, Digital Health, Boehringer Ingelheim

Lauren Li, Head of Digital Health, Ipsen

Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Paul Upham, Head, Smart Devices, Roche / Genentech

Rachel Sha, Vice President, Digital Business Development, Sanofi

10:25am
Speed Networking

Location: Networking Area

 

Through the purpose built Networking on function, get ready to expand your network through randomly assigned 1 on 1 quick fire interactions. You can choose who you want to “connect” and then set-up 1-2-1 in-depth meetings throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

10:25am
Open Q&A with Speakers

Location: Sessions

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

 

Michael Latauska, Director, Digital Health, Boehringer Ingelheim

Lauren Li, Head of Digital Health, Ipsen

Joris van Dam, Executive Director, Head of Digital Therapeutics, Novartis

Paul Upham, Head, Smart Devices, Roche / Genentech

Rachel Sha, Vice President, Digital Business Development, Sanofi

10:55am
Life Admin Break

Catch-up on emails, let the dog out, brew some more coffee… use this time to take care of regular day-to-day life.

Location: Stage

11:15am
Presentation: An Insight into European Digital Therapeutics Regulation and an Update on the new German Legislation
  • A deep-dive into the process of obtaining DTx reimbursement through the new German legislation
  • How has this changed DTx reimbursement opportunities in Germany?
  • How are GAIA’s digital therapeutics moving through this new reimbursement pathway?

 

Matthias Zenker, Partner, GAIA AG

11:30am
Presentation: Improving Behavioral Health through Virtual Reality Digital Therapeutics

Why VR is such an appealing medium for behavioral health interventions
How COVID-19 has accelerated the coupling of digital therapeutics and telehealth
A look at BehaVR’s products, pipeline and results so far

 

Aaron Gani, Founder & Chief Executive Officer, BehaVR

11:45am
Wellness Break
11:55am
Presentation: Becoming a Virtual Sleep Disorder Provider
  • How is Dreem enabling access to sleep in a similar way to a healthcare provider
  • Showcase of real world evidence on Dreem’s insomnia therapy studies
  • Discussion will focus on the personalization of digital therapeutics

 

Vik Panda, Managing Director, North America, Dreem

Location: Sessions

11:15am
Interactive Open Mic Session

This open mic session will enable you to suggest the topics you would like to hear more about.

If there was a topic that was covered in the agenda but you wish to go deeper, or a new topic that wasn’t showcased, this is your chance to discuss with peers. The choice is yours!

Facilitators will initiate the discussion and ensure that topics are stuck to and will cultivate guidance and answers to your questions.

Actively or passively take part in this discussion.

 

Owen McCarthy, Co-Founder & President, MedRhythms

Andy Molnar, Vice President, Market Access, Cognoa

12:10pm
Panel Discussion: A Minds Eye View of Digital Therapeutics - An Investor Perspective

Location: Stage

As the digital therapeutics enters the next phase in its lifecycle, the sentiment from the investor community is changing. Tap into the mind of leading investors to understand how digital therapeutic companies and their partners should alter their approaches. Hear the experts’ thoughts on:

  • What are investors looking for from digital therapeutic companies to prompt them to pull the trigger on investment?
  • How has Covid-19 impacted our assessment of the investment opportunities in digital therapeutics?
  • How can DTx companies prepare to secure multiple rounds of funding from the start?
  • Where do investors think the risk lies in investing in digital therapeutics?
  • How can DTx best source the right investment partner to ensure future success?

 

Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma

Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund

Zack Lynch, Managing Partner, JAZZ Venture Partners 

Caleb Winder, Managing Director, MemorialCare Innovation Fund

12:40pm
Open Q&A with Speakers

Location: Sessions

 

This is your chance to pose your burning questions to the expert speakers from the previous panel.

 

Chihiro Hosoya, Head of Venture Management & Business Development, Rx+ Business Accelerator, Astellas Pharma

Debbie Lin, Executive Director, Boehringer Ingelheim Venture Fund

Zack Lynch, Managing Partner, JAZZ Venture Partners 

Caleb Winder, Managing Director, MemorialCare Innovation Fund

1:00pm
Close of DTx East 2020

Roll straight into your weekend, with no flight to catch!

Download Full Agenda

On-Demand Content

  • On-Demand Presentations
On-Demand Presentations
Attendees will be able to access these pre-recorded presentations throughout the entire conference.
The Potential of Digital Therapeutics for Treatment in the Real World
  • S-Alpha therapeutics is trying to discover real world area, can be managed by digital therapeutics
  • An example of development of digital therapeutics which has been discovered according to real world area
  • Insight to reach out to the market with digital therapeutics in the real world

Seung Eun Choi, Chief Executive Officer, S-Alpha Therapeutics

Combining Haptics with Cognitive Approaches to Deliver a Bottom-up Intervention - A Case Study by Embr Labs
  • How is Embr Labs combining haptics with cognitive approaches to deliver an innovative digital therapeutic?
  • How thermal stimulation complements traditional cognitive approaches in digital therapeutics
  • How is Embr Labs shifting from a consumer wellness product to an FDA approved therapeutic?

Martha Menard, Senior Scientist, Embr Labs

Elizabeth Gazda, Chief Executive Officer, Embr Labs

MedRhythms Digital Therapeutics Evidence Generation
  • A look at Neuroscience and clinical foundation in the context of digital therapeutics
  • Showcasing of flagship product evidence in stroke patients
  • This presentation will also showcase evidence generation of products being developed to treat Multiple Sclerosis

Brian Harris, Chief Executive Officer, MedRhythms

Download Full Agenda

Partner With Us

DTx East being online presents an opportunity for us to super-charge our offering. We have selected the best-in-class platform to offer our attendees a wide range of options to learn, network, and collaborate. The result, bringing together the best DTx audience of the year.

Making your session engaging and knowledgeable will attract the largest audience.  We will guide you on how best to maximize the benefits of using our platform.

No need to sit behind a desk!  Our networking tools enable attendees to arrange 121 video conversations as well as taking part in curated networking sessions. You could potentially meet many more people than you would in a typical venue setting.

Get in touch to learn more about the options available at Digital DTx.

Contact Us +
Partner With Us

Register for the Event

For pricing and booking options for DTx East 2020 please click the button to go to the registration page.

Registration